Membrane-bound IL-7 Engineered TIL therapy for advanced ovarian cancer

crossref(2024)

引用 0|浏览2
暂无评分
摘要
Abstract Ovarian cancer lacks effective therapy. Here, we reported three metastatic ovarian cancer patients administrated with a noval TIL therapy, which was designed glycosylphosphatidylinositol-anchored membrane-bound interleukin-7 (mbIL-7-GPI) to engineer TILs (mbIL-7-TIL) through piggyBac transposon system. In three advanced ovarian cancer patients, infusion of mbIL-7-TILs showed endurable toxicity and prolonged clinical response. After infusion, peripheral mbIL-7-TILs peaked around 5-7 days and then sharply decreased. We found that several clones of engineered T cell and subsequent clones of original T cells underwent significant proliferation in patient 1. Seven months post infusion, mbIL-7-TILs could be detected in tumor liquefactive necrosis of patient 2. These findings indicated that mbIL-7-TILs could efficiently home to tumor lesions and sustainably enhance antitumor immunity in situ, suggesting potent therapeutics to treat advanced OC.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要